Pharmacology of heterologously expressed KATP channels
| Tissue | Molecular Composition | Dia | Pina | P-1075 | Gly | 5HD | HMR-1098 |
|---|---|---|---|---|---|---|---|
| Kir6.1/SUR1 | O | O | NE | C | C | NE | |
| Kir6.1/SUR2A | NE | O | O | C | NE | NE | |
| VSM | Kir6.1/SUR2B | O | O | O | C | NE | NE |
| Pancreatic | Kir6.2/SUR1 | O | O | O | C | C | C |
| Sarcolemmal | Kir6.2/SUR2A | NE | O | O | C | NE | C |
| VSM | Kir6.2/SUR2B | NE | O | O | C | NE | NE |
| Mitochondria | Unknown | O | O | NE | C | C | NE |
VSM, vascular smooth muscle; Dia, diazoxide (100 μM); Pina, pinacidil (100 μM); P-1075 (100 μM); Gly, glybenclamide (10 μM); 5HD, 5-hydroxydecanonic acid sodium (200 μM); HMR-1098 (10 μM); O, open; C, close; NE, no effect.
The information about tissue specific distribution of KATPchannels was taken from Yokoshiki et al. (1998) and Hu et al. (1999).